Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Uprima Selective ED Population Should Be Reflected In Labeling, Cmte. Says

Executive Summary

TAP's Uprima labeling should describe the selective population of men with erectile dysfunction who were enrolled in clinical trials of the drug, FDA's Reproductive Health Drugs Committee Urologics Subcommittee said April 10.

You may also be interested in...



TAP Uprima Erectile Dysfunction NDA Refiling Slated For 4Q, Abbott Says

TAP will refile an NDA for the erectile dysfunction disorder drugUprima in the fourth quarter, Abbott Pharmaceuticals President Jeff Leiden, MD/PhD, told analysts on a first quarter conference call April 9

TAP Uprima Erectile Dysfunction NDA Refiling Slated For 4Q, Abbott Says

TAP will refile an NDA for the erectile dysfunction disorder drugUprima in the fourth quarter, Abbott Pharmaceuticals President Jeff Leiden, MD/PhD, told analysts on a first quarter conference call April 9

TAP Uprima 3 Mg Dose Studies To Be Completed This Summer; NDA Withdrawn

TAP expects to complete additional Uprima efficacy and safety studies using a 3 mg dose this summer.

UsernamePublicRestriction

Register

ID1122310

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel